The use of bone substitutes and adjuvant antibiotic therapy in peri-implantitis surgery: a randomised controlled clinical trial

niversity Medical Center Groningen0 个研究点目标入组 123 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•the patient is =18 years of age;
•- adult patients with at least one endosseous implant in the oral cavity with clinical and radiographical evidence of peri-implantitis. Peri-implantitis is defined as probing pocket depth (PPD) of = 6mm in combination with bleeding on probing (BOP) or suppuration on probing (SOP) and radiographic bone loss of =3mm after placing the definitive suprastructure (Berglundh et al. 2018);
•- the implants have been in function for at least 2 years;
•- the patient is capable of understanding and giving informed consent.

•Exclusion criteria prior to pre-treatment:
•- medical and general contra-indications for the procedure;
•- a history of local radiotherapy to the head and neck region;
•- pregnancy and lactation;
•- uncontrolled diabetes mellitus (HbA1c <7% or <53 mmol/mol);
•- use of intravenous bisphosphonates;
•- known allergy to chlorhexidine, amoxicillin and/or metronidazole;
•- long-term use of anti-inflammatory drugs
•- patient is incapable of performing basic oral hygiene measures as a result of physical or mental disorders;
•- implants with bone loss exceeding 2/3 of implant length or implants with bone loss beyond the transverse openings in hollow implants;
•- previous surgical treatment of the peri-implantitis lesions;
•- chronic bronchitis or asthma.
•Additional exclusion criteria after pre-treatment:
•- no peri-implantitis remaining: minor BoP (< 20%), PPD < 6mm, plaque < 20%;
•- active periodontal disease at the remaining dentition (PPD = 6mm, BOP = 20%) or insufficient oral hygiene (plaque = 20%);
•- use of antibiotics during the last 3 months.

发起方